Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Cryoablation for Monomorphic Ventricular Tachycardia (VTS)

← catalyst calendar

NCT07650032 · readout in 224 d

Sponsored by Adagio Medical (industry) · ADGM — their whole pipeline →.

Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
10
Countries
Canada, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2026-08-01estimatedWhen the study began enrolling
Primary completion2027-03-31estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2027-09-30estimatedThe whole study's end, after follow-up
First posted2026-06-16actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-08-12actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Ventricular Tachycardia, Sustained
  • Ventricular Tachycardia, Monomorphic

Intervention

  • Device: Ultra Low Temperature Ablation (ULTA)

Primary outcomes

what the primary-completion date above is the date OF
Primary Safety Endpoint - Freedom from definite or probable device or procedure related Major Adverse Events (MAEs) that occur within 7 days following the ablation procedure.
measured 7 days following the ablation procedure
Primary Efficacy Endpoint - Freedom from recurrent sustained MMVT in the absence of a new AAD or increase in dose of a pre-ablation AAD for VT management at 6 months following the ablation procedure
measured 6 months after the procedure
Primary Procedural Endpoint - Percentage of non-inducibility VT targeted for ablation post-procedure
measured at the end of the ablation procedure

Permalink · ADGM's whole pipeline · Catalyst calendar · Every registered study · What changed